JP2019537589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537589A5 JP2019537589A5 JP2019522974A JP2019522974A JP2019537589A5 JP 2019537589 A5 JP2019537589 A5 JP 2019537589A5 JP 2019522974 A JP2019522974 A JP 2019522974A JP 2019522974 A JP2019522974 A JP 2019522974A JP 2019537589 A5 JP2019537589 A5 JP 2019537589A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation according
- capsaicin
- polyethylene glycol
- solubilizer
- polyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 134
- 238000002360 preparation method Methods 0.000 claims description 129
- 229960002504 capsaicin Drugs 0.000 claims description 65
- 235000017663 capsaicin Nutrition 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 49
- -1 polyethylene Polymers 0.000 claims description 47
- 239000002202 Polyethylene glycol Substances 0.000 claims description 46
- 229920001223 polyethylene glycol Polymers 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 46
- 239000004698 Polyethylene Substances 0.000 claims description 40
- 229920000573 polyethylene Polymers 0.000 claims description 40
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims description 38
- 238000009472 formulation Methods 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 15
- 230000003204 osmotic effect Effects 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 12
- 239000007972 injectable composition Substances 0.000 claims description 12
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical group CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 239000003607 modifier Substances 0.000 claims description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 6
- 208000006820 Arthralgia Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 210000000629 knee joint Anatomy 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000003797 carpal joint Anatomy 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 description 1
- 229960002860 zucapsaicin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416345P | 2016-11-02 | 2016-11-02 | |
| US62/416,345 | 2016-11-02 | ||
| PCT/US2017/059628 WO2018085476A1 (en) | 2016-11-02 | 2017-11-02 | Stable aqueous capsaicin injectable formulations and medical uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537589A JP2019537589A (ja) | 2019-12-26 |
| JP2019537589A5 true JP2019537589A5 (https=) | 2020-12-10 |
| JP7100635B2 JP7100635B2 (ja) | 2022-07-13 |
Family
ID=62077165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522974A Active JP7100635B2 (ja) | 2016-11-02 | 2017-11-02 | 安定な水性カプサイシン注射製剤およびその医学的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US11000490B2 (https=) |
| EP (1) | EP3534961B1 (https=) |
| JP (1) | JP7100635B2 (https=) |
| KR (1) | KR102657458B1 (https=) |
| CN (1) | CN110035740B (https=) |
| AU (1) | AU2017353782B2 (https=) |
| CA (1) | CA3041121A1 (https=) |
| IL (1) | IL266279B2 (https=) |
| MX (1) | MX2019005202A (https=) |
| NZ (1) | NZ752750A (https=) |
| WO (1) | WO2018085476A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102657458B1 (ko) | 2016-11-02 | 2024-04-12 | 센트렉시온 테라퓨틱스 코포레이션 | 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도 |
| WO2019018769A1 (en) | 2017-07-20 | 2019-01-24 | Centrexion Therapeutics Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE |
| EP3840739B1 (en) * | 2018-08-24 | 2025-11-12 | Centrexion Therapeutics Corporation | Capsaicin sequential dosing method for treatment of knee joint pain |
| KR20210151949A (ko) | 2020-04-05 | 2021-12-14 | 화이자 인코포레이티드 | Covid-19의 치료를 위한 화합물 및 방법 |
| CN113855626B (zh) * | 2020-08-07 | 2023-03-24 | 北京泰德制药股份有限公司 | 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法 |
| TR2021013305A2 (tr) * | 2021-08-23 | 2023-03-21 | Tuem Ekip Ilac Anonim Sirketi | Li̇yofi̇li̇ze levosi̇mendan formülasyonlari |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599342A (en) | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
| US5099030A (en) | 1987-03-09 | 1992-03-24 | The Procter & Gamble Company | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain |
| US5021450A (en) | 1989-05-30 | 1991-06-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
| US5431914A (en) | 1992-04-17 | 1995-07-11 | Adekunle; Michael | Method of treating an internal condition by external application of capsaicin without the need for systemic absorption |
| US5985860A (en) | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
| US5318960A (en) | 1992-06-03 | 1994-06-07 | Frank Toppo | System for transdermal delivery of pain relieving substances |
| EP0646372B1 (de) | 1993-09-30 | 1999-03-31 | Medichemie Ag | Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie |
| US6248788B1 (en) | 1996-11-06 | 2001-06-19 | The Regents Of The University Of California | Therapeutic method with capsaicin and capasicin analogs |
| WO1998020867A1 (en) | 1996-11-15 | 1998-05-22 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists |
| US6060060A (en) | 1997-01-31 | 2000-05-09 | Bmb Patent Holding Corporation | Analgesic compositions from sweet peppers and methods of use thereof |
| ATE219674T1 (de) | 1997-03-13 | 2002-07-15 | James N Campbell | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika |
| EP0984781A1 (en) | 1997-05-27 | 2000-03-15 | Algos Pharmaceutical Corporation | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
| US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
| CA2442049C (en) | 2001-03-22 | 2010-06-01 | Michael J. Iadarola | Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist |
| US20030104085A1 (en) | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
| JP2005538983A (ja) | 2002-07-19 | 2005-12-22 | メステックス アクチエンゲゼルシャフト | 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法 |
| PT1605956E (pt) | 2002-12-18 | 2016-03-09 | Centrexion Therapeutics Corp | Administração de capsaicinóides para o tratamento da osteoartrite |
| US20040156931A1 (en) | 2002-12-18 | 2004-08-12 | Algorx | Administration of capsaicinoids |
| US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
| RU2373953C2 (ru) | 2003-12-19 | 2009-11-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированная композиция, содержащая полипептид фактора vii |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| EA200701131A1 (ru) * | 2004-11-24 | 2007-12-28 | Алгоркс Фармасьютикалз, Инк. | Гелеобразная препаративная форма капсаициноида и способы её применения |
| DE502004011941D1 (de) | 2004-12-22 | 2011-01-05 | Mestex Ag | Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels |
| ES2533256T3 (es) | 2004-12-28 | 2015-04-08 | Mestex Ag | Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor |
| EP1830835B1 (de) | 2004-12-28 | 2012-03-14 | Mestex AG | Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan f]r die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
| US20080160487A1 (en) | 2006-12-29 | 2008-07-03 | Fairfield Language Technologies | Modularized computer-aided language learning method and system |
| US8222564B2 (en) | 2008-02-13 | 2012-07-17 | Tyco Healthcare Group, Lp | Methods of altering surgical fiber |
| US8158682B2 (en) | 2008-09-12 | 2012-04-17 | Vallinex, Inc. | Instillation administration of capsaicinoids for the treatment of pain |
| JP6002385B2 (ja) | 2008-09-12 | 2016-10-05 | クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ | 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法 |
| CN101507818B (zh) | 2008-12-15 | 2010-11-10 | 中国人民武装警察部队医学院 | 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶 |
| US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| US20130303495A1 (en) | 2009-12-31 | 2013-11-14 | Sov Therapeutics | Emulsion formulations |
| TW201302681A (zh) | 2011-03-25 | 2013-01-16 | Abbott Lab | Ｔｒｐｖ１拮抗劑 |
| EP3388057B1 (en) | 2011-09-09 | 2022-03-09 | Propella Therapeutics, Inc. | A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof |
| ES2699806T3 (es) | 2012-04-18 | 2019-02-12 | SpecGx LLC | Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata |
| CA2868416A1 (en) | 2012-04-18 | 2013-10-24 | Mallinckrodt Llc | Immediate release pharmaceutical compositions with abuse deterrent properties |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| JP2015523401A (ja) | 2012-08-03 | 2015-08-13 | メステックス・アー・ゲー | レシニフェラトキシン溶液 |
| AU2013341380B2 (en) * | 2012-11-12 | 2018-04-26 | Propella Therapeutics, Inc. | Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid |
| GB201304662D0 (en) * | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
| WO2014132134A1 (en) * | 2013-02-28 | 2014-09-04 | Pronova Biopharma Norge As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
| GB201317756D0 (en) | 2013-10-08 | 2013-11-20 | Critical Pharmaceuticals Ltd | New process |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| GB201319792D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US20150133561A1 (en) * | 2013-11-12 | 2015-05-14 | Vizuri Health Sciences Llc | Aqueous based capsaicinoid formulations and methods of manufacture and use |
| JP6487452B2 (ja) | 2014-01-24 | 2019-03-20 | センティス ファーマ プライベート リミテッド | ブリンゾラミドを含む医薬組成物 |
| US20170042834A1 (en) | 2014-04-14 | 2017-02-16 | Flex Pharma, Inc. | Ion channel activators and methods of use |
| WO2015160842A1 (en) * | 2014-04-14 | 2015-10-22 | Flex Pharma, Inc. | Methods and formulatiions of capsaicinoids and capsinoids |
| MX377377B (es) | 2014-04-15 | 2025-03-10 | Propella Therapeutics Inc | Composiciones tópicas para el alivio del dolor, manufactura y uso. |
| CN105030760B (zh) | 2014-04-24 | 2018-10-02 | 长弘生物科技股份有限公司 | 稳定医药组合物 |
| JP6855248B2 (ja) | 2014-06-25 | 2021-04-07 | ヌカナ ピーエルシー | ゲムシタビン−プロドラッグを含む製剤 |
| WO2015198350A1 (en) | 2014-06-25 | 2015-12-30 | Synergia Bio Sciences Private Limited | A pharmaceutical oil-in-water nano-emulsion |
| KR20170066344A (ko) | 2014-08-19 | 2017-06-14 | 만디쇼라 이스라엘 무자리 | 약제로서의 캡시노이드 및 그의 용도 |
| JP2017534656A (ja) | 2014-11-13 | 2017-11-24 | セントレクシオン セラピューティクス コーポレイション | 肢端舐性肉芽腫の治療に使用するためのカプサイシノイド |
| US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| WO2016126540A1 (en) | 2015-02-02 | 2016-08-11 | Enspire Group LLC | Stabilized dialkyl fumarate compositions |
| CA2987517A1 (en) | 2015-05-29 | 2016-12-08 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition of isotretinoin |
| CA3254279A1 (en) | 2015-06-03 | 2025-03-18 | Triastek, Inc. | PHARMACEUTICAL FORMS AND RELATED USES |
| WO2017087803A1 (en) | 2015-11-20 | 2017-05-26 | Sorrento Therapeutics, Inc. | Methods for pain treatment using resiniferatoxin |
| US9989978B2 (en) | 2016-01-21 | 2018-06-05 | Itt Manufacturing Enterprises Llc | Natural gas pressure regulator having adjustable valve seat |
| EP3405187A4 (en) | 2016-01-22 | 2019-07-31 | Centrexion Therapeutics Corporation | SEQUENCING DOSAGE METHOD FOR CAPSAICN FOR THE TREATMENT OF MORTON NEUROM |
| WO2017147146A1 (en) | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
| EP3463576A4 (en) | 2016-05-25 | 2020-01-15 | Concentric Analgesics, Inc. | PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA |
| KR102657458B1 (ko) | 2016-11-02 | 2024-04-12 | 센트렉시온 테라퓨틱스 코포레이션 | 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도 |
| WO2018217937A1 (en) | 2017-05-24 | 2018-11-29 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
-
2017
- 2017-11-02 KR KR1020197015747A patent/KR102657458B1/ko active Active
- 2017-11-02 MX MX2019005202A patent/MX2019005202A/es unknown
- 2017-11-02 CN CN201780075307.XA patent/CN110035740B/zh active Active
- 2017-11-02 AU AU2017353782A patent/AU2017353782B2/en active Active
- 2017-11-02 NZ NZ752750A patent/NZ752750A/en unknown
- 2017-11-02 EP EP17868308.2A patent/EP3534961B1/en active Active
- 2017-11-02 CA CA3041121A patent/CA3041121A1/en active Pending
- 2017-11-02 JP JP2019522974A patent/JP7100635B2/ja active Active
- 2017-11-02 WO PCT/US2017/059628 patent/WO2018085476A1/en not_active Ceased
- 2017-11-02 US US16/342,652 patent/US11000490B2/en active Active
-
2019
- 2019-04-28 IL IL266279A patent/IL266279B2/en unknown
- 2019-05-01 US US16/400,278 patent/US10493047B2/en active Active
- 2019-11-26 US US16/695,831 patent/US10765649B2/en active Active
- 2019-11-26 US US16/695,824 patent/US10772853B2/en active Active
-
2020
- 2020-09-11 US US17/018,148 patent/US11344516B2/en active Active
-
2022
- 2022-03-22 US US17/701,160 patent/US11992470B2/en active Active
-
2024
- 2024-05-24 US US18/674,288 patent/US20240423931A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537589A5 (https=) | ||
| ES2336034T3 (es) | Composiciones de diclofenaco inyectables estables. | |
| RU2016139373A (ru) | Растворы бупренорфина с замедленным высвобождением | |
| KR20180001587A (ko) | 안정화된 안과용 갈락토만난 제제 | |
| CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
| US20150051168A1 (en) | Stable liquid pharmaceutical composition containing piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt and the manufacturing method thereof | |
| JP2020527574A5 (https=) | ||
| RU2011136694A (ru) | КОМПЛЕКС ПЕПТИДА-ИНГИБИТОРА TGF-β1 И ЦИКЛОДЕКСТРИНА ИЛИ ЕГО ПРОИЗВОДНОГО, ЭМУЛЬСИЯ ПЕПТИДА-ИНГИБИТОРА TGF-β1, ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ ВЫШЕУКАЗАННЫХ КОМПЛЕКСА И ЭМУЛЬСИИ, ПРОДУКТ, ПОЛУЧЕННЫЙ ВЫШЕУПОМЯНУТЫМИ СПОСОБАМИ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ И/ИЛИ СОСТОЯНИЯ, ОПОСРЕДОВАННОГО TGF-β1 | |
| JP5759720B2 (ja) | 濃縮エスモロール | |
| WO2018073269A1 (en) | Liquid formulations of daptomycin | |
| JP5872551B2 (ja) | パラセタモールを含む医薬組成物およびその製造法 | |
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| CN101677943B (zh) | 使用苯甲醇的多剂量浓缩艾司洛尔 | |
| TWI649097B (zh) | 乙醯胺酚之可注射製劑 | |
| RU2008126108A (ru) | Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту | |
| JP2024522892A (ja) | 薬学的組成物 | |
| JP2022089867A (ja) | 安定なイブプロフェン注射製剤用組成物 | |
| RU2019116788A (ru) | Стабильные водные инъекционные составы капсаицина и их медицинские применения | |
| RU2020115819A (ru) | Фармацевтические составы, содержащие агонист опиоидных рецепторов в качестве активного ингредиента, способы их получения и их терапевтическое применение | |
| JP2014528477A5 (ja) | 急性腎臓損傷を治療するための組成物及び溶液 | |
| TR201902890A2 (tr) | İbuprofen İçeren Enjektabl Çözelti Formunda Yeni Bir Farmasötik Kompozisyon | |
| WO2020025986A1 (en) | Injectable combination of diclofenac sodium and thiocolchicoside |